GH- NAS (USA) Also traded in: Germany, Mexico
Guardant Health Inc

Not Rated

Top Ranked Predictable Companies

$34.12

0.64(1.83%) Volume: 605,318 12:52PM EDT

Avg Vol (1m): 1,440,830

Warning! GuruFocus has detected 4 Severe Warning Signs with NAS:GH. Click here to check it out.

Market Cap : 3.51 B	Enterprise Value : 3.96 B	PE Ratio : At Loss	PB Ratio : 6.34

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- GF Score
- GF Value Rank
- Growth Rank
- Insider Ownership
- Institutional Ownership
- Market Cap
- Momentum Rank
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Probability of Financial Distress (%)
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Capex-to-Operating-Cash-Flow
- Capex-to-Operating-Income
- Capex-to-Revenue
- Cash Conversion Cycle
- Cash Ratio
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-FCF
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- Liabilities-to-Assets
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- EBITDA Margin %
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
- Volatility
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow Statement
- All Taxes Paid
- Asset Impairment Charge
- Beginning Cash Position
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- Ending Cash Position
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid
Technical Indicator
- 5-Day RSI
- 9-Day RSI
- 14-Day RSI
- 50-Day SMA
- 6-Month Price Index
- 6-1 Month Momentum %
- 12-1 Month Momentum %

Guardant Health LT-Debt-to-Total-Asset

: 0.64 (As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Guardant Health's long-term debt to total assests ratio for the quarter that ended in Mar. 2022 was 0.64.

Guardant Health's long-term debt to total assets ratio increased from Mar. 2021 (0.57) to Mar. 2022 (0.64). It may suggest that Guardant Health is progressively becoming more dependent on debt to grow their business.

Guardant Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Guardant Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

0.04

0.37

0.62

Guardant Health Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
LT-Debt-to-Total-Asset																0.57	0.59	0.61	0.62	0.64

Guardant Health LT-Debt-to-Total-Asset Calculation

Guardant Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	1360.874	/	2204.499
	=	0.62

Guardant Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2022 is calculated as

LT Debt to Total Assets (Q: Mar. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2022 )	/	Total Assets (Q: Mar. 2022 )
	=	1360.84	/	2129.598
	=	0.64

Guardant Health (NAS:GH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Guardant Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Guardant Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071

Comparable Companies

MIL:DIA NAS:SYNH NAS:SHC SHSE:603882 NAS:MEDP SHSE:603127 SZSE:300676 NAS:OCDX NYSE:QGEN NAS:LNTH

Traded in Other Exchanges

GH:Mexico 5GH:Germany

Address

505 Penobscot Drive, Redwood City, CA, USA, 94063

Website

https://www.guardanthealth.com

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Executives

Talasaz Amirali	director, officer: Chairman, President and COO	18 ISABELLA AVENUE ATHERTON CA 94027
Kaul Samir	director	C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025
Meresman Stanley J	director	2071 HUNTINGTON LANE LOS ALTOS CA 94024
Svf Bluebird (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Svf Enterprise (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Sb Investment Advisers (uk) Ltd	10 percent owner	69 GROSVENOR STREET LONDON X0 W1K 3JP
Softbank Vision Fund (aiv M1) L.p.	10 percent owner	251 LITTLE FALLS DRIVE WILMINGTON DE 19808
Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Clark Ian T	director	SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Eltoukhy Helmy	director, officer: Chief Executive Officer	2 BARRY LANE ATHERTON CA 94027
Bertocci Derek A	officer: Chief Financial Officer	3070 ORCHARD DRIVE SAN JOSE CA 95134
Saia John G.	officer: See Remarks	C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063
Gadde Vijaya	director	C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103
Jallal Bahija	director	120 MONUMENT CIRCLE INDIANAPOLIS IN 46204
Nishar Dipchand	director	C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043

Guardant Health Headlines

From GuruFocus

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

By Business Wire 10-05-2021

New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360� Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer

By Marketwired 09-07-2021

Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360� Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium

By Business Wire 12-06-2021

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR�-2 Blood Test to Detect Colorectal Cancer

By Business Wire 12-17-2021

Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

By Business Wire 08-06-2021

Study Shows Guardant360� Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

By Business Wire 11-11-2021

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

By Business Wire 11-04-2021

Iron Triangle Partners LP Buys DaVita Inc, NanoString Technologies Inc, UnitedHealth Group Inc, Sells Humana Inc, Horizon Therapeutics PLC, Hologic Inc

By insider 02-19-2022

Guardant Health Appoints Myrtle Potter to Its Board of Directors

By Business Wire 10-20-2021

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

By Business Wire 01-19-2022

Other Sources

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

By Zacks 2022-01-26

Bull of the Day: Exact Sciences (EXAS)

By Zacks 2021-07-19

$GH - Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript. Guardant Health Inc Gh Q4 2021 Results Earnings Call Transcript

By Seekingalpha 2022-02-23

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

By Seekingalpha 2022-02-24

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

Guardant Health LT-Debt-to-Total-Asset

Guardant Health LT-Debt-to-Total-Asset Historical Data

Guardant Health LT-Debt-to-Total-Asset Calculation

Guardant Health LT-Debt-to-Total-Asset Related Terms

Guardant Health Business Description

Guardant Health Headlines

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal� Blood Test to Predict Recurrence Across Early-Stage Cancers

New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360� Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer

Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360� Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR�-2 Blood Test to Detect Colorectal Cancer

Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

Study Shows Guardant360� Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

Iron Triangle Partners LP Buys DaVita Inc, NanoString Technologies Inc, UnitedHealth Group Inc, Sells Humana Inc, Horizon Therapeutics PLC, Hologic Inc

Guardant Health Appoints Myrtle Potter to Its Board of Directors

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

Bull of the Day: Exact Sciences (EXAS)

$GH - Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript. Guardant Health Inc Gh Q4 2021 Results Earnings Call Transcript

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Looking for Growth? Check Out These 2 Diagnostics Stocks

Why Guardant Health Jumped Nearly 5% on Tuesday

Bear of the Day: NeoGenomics (NEO)

$GH - Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation. Guardant Health Inc 2021 Q4 Results Earnings Call Presentation

$GH - Guardant Health (GH) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference.…

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

$GH - Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q3 2021 Results - Earnings Call Transcript.…

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

Why Guardant Health Fell More Than 5% Today

Why Earnings Season Could Be Great for Guardant Health (GH)

After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)